Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) EBT Margin (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of EBT Margin readings, the most recent being 64.0% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 6989.0% to 64.0% in Q4 2025 year-over-year; TTM through Dec 2025 was 108.62%, a 5125.0% increase, with the full-year FY2025 number at 127.9%, up 4625.0% from a year prior.
  • EBT Margin hit 64.0% in Q4 2025 for Enanta Pharmaceuticals, up from 123.42% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 64.0% in Q4 2025 to a low of 211.37% in Q1 2023.
  • Median EBT Margin over the past 5 years was 149.66% (2021), compared with a mean of 149.11%.
  • Biggest five-year swings in EBT Margin: tumbled -10888bps in 2021 and later soared 7638bps in 2025.
  • Enanta Pharmaceuticals' EBT Margin stood at 109.05% in 2021, then decreased by -13bps to 123.04% in 2022, then tumbled by -54bps to 189.02% in 2023, then grew by 29bps to 133.89% in 2024, then skyrocketed by 52bps to 64.0% in 2025.
  • The last three reported values for EBT Margin were 64.0% (Q4 2025), 123.42% (Q3 2025), and 99.52% (Q2 2025) per Business Quant data.